cancer research uk trading limited
cancer research uk trading limited Company Information
Company Number
04355631
Next Accounts
Dec 2025
Shareholders
cancer research uk
Group Structure
View All
Industry
Other retail sale in non-specialised stores
+2Registered Address
2 redman place, london, E20 1JQ
Website
www.cancerresearchuk.orgcancer research uk trading limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH UK TRADING LIMITED at £14.7m based on a Turnover of £30.7m and 0.48x industry multiple (adjusted for size and gross margin).
cancer research uk trading limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH UK TRADING LIMITED at £1.9m based on an EBITDA of £451.8k and a 4.18x industry multiple (adjusted for size and gross margin).
cancer research uk trading limited Estimated Valuation
Pomanda estimates the enterprise value of CANCER RESEARCH UK TRADING LIMITED at £797.5k based on Net Assets of £336k and 2.37x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cancer Research Uk Trading Limited Overview
Cancer Research Uk Trading Limited is a live company located in london, E20 1JQ with a Companies House number of 04355631. It operates in the other retail sale in non-specialised stores sector, SIC Code 47190. Founded in January 2002, it's largest shareholder is cancer research uk with a 100% stake. Cancer Research Uk Trading Limited is a mature, large sized company, Pomanda has estimated its turnover at £30.7m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Cancer Research Uk Trading Limited Health Check
Pomanda's financial health check has awarded Cancer Research Uk Trading Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 7 areas for improvement. Company Health Check FAQs
5 Strong
0 Regular
7 Weak
Size
annual sales of £30.7m, make it larger than the average company (£761.1k)
£30.7m - Cancer Research Uk Trading Limited
£761.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 33%, show it is growing at a faster rate (8.3%)
33% - Cancer Research Uk Trading Limited
8.3% - Industry AVG
Production
with a gross margin of 7.8%, this company has a higher cost of product (40.6%)
7.8% - Cancer Research Uk Trading Limited
40.6% - Industry AVG
Profitability
an operating margin of 1.4% make it less profitable than the average company (4.8%)
1.4% - Cancer Research Uk Trading Limited
4.8% - Industry AVG
Employees
with 201 employees, this is above the industry average (14)
201 - Cancer Research Uk Trading Limited
14 - Industry AVG
Pay Structure
on an average salary of £37.6k, the company has a higher pay structure (£26.3k)
£37.6k - Cancer Research Uk Trading Limited
£26.3k - Industry AVG
Efficiency
resulting in sales per employee of £152.7k, this is more efficient (£108k)
£152.7k - Cancer Research Uk Trading Limited
£108k - Industry AVG
Debtor Days
it gets paid by customers after 15 days, this is earlier than average (19 days)
15 days - Cancer Research Uk Trading Limited
19 days - Industry AVG
Creditor Days
its suppliers are paid after 18 days, this is quicker than average (34 days)
18 days - Cancer Research Uk Trading Limited
34 days - Industry AVG
Stock Days
it holds stock equivalent to 91 days, this is more than average (65 days)
91 days - Cancer Research Uk Trading Limited
65 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (35 weeks)
0 weeks - Cancer Research Uk Trading Limited
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 96.7%, this is a higher level of debt than the average (59.2%)
96.7% - Cancer Research Uk Trading Limited
59.2% - Industry AVG
CANCER RESEARCH UK TRADING LIMITED financials
Cancer Research Uk Trading Limited's latest turnover from March 2024 is £30.7 million and the company has net assets of £336 thousand. According to their latest financial statements, Cancer Research Uk Trading Limited has 201 employees and maintains cash reserves of £87 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 30,691,000 | 28,673,000 | 24,674,000 | 13,192,000 | 26,962,000 | 29,663,000 | 27,840,000 | 28,358,000 | 25,709,000 | 23,655,000 | 23,003,000 | 23,742,000 | 21,772,000 | 23,017,000 | 23,767,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 28,294,000 | 22,247,000 | 19,161,000 | 8,358,000 | 21,949,000 | 20,779,000 | 20,664,000 | 21,386,000 | 20,843,000 | 19,334,000 | 18,129,000 | 18,959,000 | 19,705,000 | 22,058,000 | 22,575,000 |
| Gross Profit | 2,397,000 | 6,426,000 | 5,513,000 | 4,834,000 | 5,013,000 | 8,884,000 | 7,176,000 | 6,972,000 | 4,866,000 | 4,321,000 | 4,874,000 | 4,783,000 | 2,067,000 | 959,000 | 1,192,000 |
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | 8,000 | 3,000 | 1,000 | 1,000 | 1,000 | 1,000 | 27,000 | 21,000 | 25,000 | 27,000 | 46,000 | ||||
| Pre-Tax Profit | 304,000 | -13,000 | -15,000 | 4,854,000 | 8,672,000 | 6,993,000 | 32,000 | -1,000 | -47,000 | -47,000 | 56,000 | 5,000 | -8,000 | ||
| Tax | 32,000 | 13,000 | 15,000 | -4,817,000 | -14,000 | -9,000 | 63,000 | 1,000 | 47,000 | 47,000 | -56,000 | -5,000 | 8,000 | ||
| Profit After Tax | 336,000 | 37,000 | 8,658,000 | 6,984,000 | 95,000 | ||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | 336,000 | -95,000 | 95,000 | ||||||||||||
| Employee Costs | 7,556,000 | 5,223,000 | 4,052,000 | 2,425,000 | 4,872,000 | 4,899,000 | 4,977,000 | 3,886,000 | 3,492,000 | 3,473,000 | |||||
| Number Of Employees | 201 | 193 | 147 | 148 | |||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 563,000 | 100,000 | 91,000 | 73,000 | 131,000 | 258,000 | 426,000 | 497,000 | 337,000 | 351,000 | 212,000 | 95,000 | 107,000 | 171,000 | 179,000 |
| Intangible Assets | |||||||||||||||
| Investments & Other | 210,000 | 210,000 | 210,000 | ||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 563,000 | 100,000 | 91,000 | 73,000 | 131,000 | 258,000 | 426,000 | 497,000 | 337,000 | 351,000 | 212,000 | 95,000 | 317,000 | 381,000 | 389,000 |
| Stock & work in progress | 7,113,000 | 4,829,000 | 3,675,000 | 3,241,000 | 2,767,000 | 2,529,000 | 1,758,000 | 1,738,000 | 1,333,000 | 1,783,000 | 2,123,000 | 2,006,000 | 1,373,000 | 1,332,000 | 1,103,000 |
| Trade Debtors | 1,327,000 | 1,315,000 | 1,769,000 | 1,399,000 | 2,025,000 | 1,951,000 | 1,753,000 | 1,068,000 | 2,391,000 | 446,000 | 1,951,000 | 2,012,000 | 286,000 | 634,000 | 632,000 |
| Group Debtors | 2,558,000 | 1,537,000 | 3,829,000 | 3,955,000 | 4,532,000 | 4,096,000 | 2,632,000 | 2,916,000 | 2,229,000 | 2,597,000 | 2,905,000 | 4,017,000 | |||
| Misc Debtors | 1,141,000 | 864,000 | 402,000 | 1,336,000 | 1,201,000 | 2,293,000 | 1,719,000 | 966,000 | 1,047,000 | 1,995,000 | 601,000 | 852,000 | 530,000 | 782,000 | 728,000 |
| Cash | 87,000 | 569,000 | 493,000 | 117,000 | 144,000 | 115,000 | 683,000 | 458,000 | 241,000 | 389,000 | 395,000 | 713,000 | 188,000 | 241,000 | 276,000 |
| misc current assets | |||||||||||||||
| total current assets | 9,668,000 | 10,135,000 | 6,339,000 | 6,093,000 | 7,674,000 | 10,717,000 | 9,868,000 | 8,762,000 | 9,108,000 | 7,245,000 | 7,986,000 | 7,812,000 | 4,974,000 | 5,894,000 | 6,756,000 |
| total assets | 10,231,000 | 10,235,000 | 6,430,000 | 6,166,000 | 7,805,000 | 10,975,000 | 10,294,000 | 9,259,000 | 9,445,000 | 7,596,000 | 8,198,000 | 7,907,000 | 5,291,000 | 6,275,000 | 7,145,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 1,426,000 | 864,000 | 1,240,000 | 355,000 | 655,000 | 353,000 | 307,000 | 346,000 | 105,000 | 94,000 | 193,000 | 277,000 | 243,000 | 419,000 | |
| Group/Directors Accounts | 4,005,000 | 5,975,000 | 3,601,000 | 4,843,000 | 4,713,000 | 8,726,000 | 7,018,000 | 6,386,000 | 4,453,000 | 3,841,000 | 4,324,000 | 4,194,000 | 1,638,000 | 767,000 | 1,033,000 |
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 4,464,000 | 3,396,000 | 1,589,000 | 968,000 | 2,437,000 | 1,890,000 | 3,175,000 | 2,750,000 | 4,646,000 | 3,650,000 | 3,780,000 | 3,520,000 | 3,376,000 | 5,265,000 | 5,693,000 |
| total current liabilities | 9,895,000 | 10,235,000 | 6,430,000 | 6,166,000 | 7,805,000 | 10,969,000 | 10,193,000 | 9,136,000 | 9,445,000 | 7,596,000 | 8,198,000 | 7,907,000 | 5,291,000 | 6,275,000 | 7,145,000 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 6,000 | 6,000 | 28,000 | ||||||||||||
| total long term liabilities | 6,000 | 6,000 | 28,000 | ||||||||||||
| total liabilities | 9,895,000 | 10,235,000 | 6,430,000 | 6,166,000 | 7,805,000 | 10,975,000 | 10,199,000 | 9,164,000 | 9,445,000 | 7,596,000 | 8,198,000 | 7,907,000 | 5,291,000 | 6,275,000 | 7,145,000 |
| net assets | 336,000 | 95,000 | 95,000 | ||||||||||||
| total shareholders funds | 336,000 | 95,000 | 95,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 21,000 | 42,000 | 55,000 | 58,000 | 127,000 | 168,000 | 189,000 | 124,000 | 111,000 | 82,000 | 44,000 | 44,000 | 68,000 | 100,000 | 111,000 |
| Amortisation | |||||||||||||||
| Tax | 32,000 | 13,000 | 15,000 | -4,817,000 | -14,000 | -9,000 | 63,000 | 1,000 | 47,000 | 47,000 | -56,000 | -5,000 | 8,000 | ||
| Stock | 2,284,000 | 1,154,000 | 434,000 | 474,000 | 238,000 | 771,000 | 20,000 | 405,000 | -450,000 | -340,000 | 117,000 | 633,000 | 41,000 | 229,000 | 1,103,000 |
| Debtors | -2,269,000 | 2,566,000 | -564,000 | -2,028,000 | -3,310,000 | 646,000 | 861,000 | -968,000 | 2,461,000 | -395,000 | 375,000 | 1,680,000 | -908,000 | -1,056,000 | 5,377,000 |
| Creditors | 562,000 | -376,000 | 885,000 | -300,000 | 302,000 | 46,000 | 307,000 | -346,000 | 241,000 | 11,000 | -99,000 | -84,000 | 34,000 | -176,000 | 419,000 |
| Accruals and Deferred Income | 1,068,000 | 1,807,000 | 621,000 | -1,469,000 | 547,000 | -1,285,000 | 425,000 | -1,896,000 | 996,000 | -130,000 | 260,000 | 144,000 | -1,889,000 | -428,000 | 5,693,000 |
| Deferred Taxes & Provisions | -6,000 | -22,000 | 28,000 | ||||||||||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | -210,000 | 210,000 | |||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -1,970,000 | 2,374,000 | -1,242,000 | 130,000 | -4,013,000 | 1,708,000 | 632,000 | 1,933,000 | 612,000 | -483,000 | 130,000 | 2,556,000 | 871,000 | -266,000 | 1,033,000 |
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 8,000 | 3,000 | 1,000 | 1,000 | 1,000 | 1,000 | 27,000 | 21,000 | 25,000 | 27,000 | 46,000 | ||||
| cash flow from financing | -1,962,000 | 2,377,000 | -1,242,000 | 130,000 | -4,012,000 | 1,709,000 | 632,000 | 1,933,000 | 613,000 | -482,000 | 157,000 | 2,577,000 | 896,000 | -239,000 | 1,079,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -482,000 | 76,000 | 376,000 | -27,000 | 29,000 | -568,000 | 225,000 | 217,000 | -148,000 | -6,000 | -318,000 | 525,000 | -53,000 | -35,000 | 276,000 |
| overdraft | |||||||||||||||
| change in cash | -482,000 | 76,000 | 376,000 | -27,000 | 29,000 | -568,000 | 225,000 | 217,000 | -148,000 | -6,000 | -318,000 | 525,000 | -53,000 | -35,000 | 276,000 |
cancer research uk trading limited Credit Report and Business Information
Cancer Research Uk Trading Limited Competitor Analysis
Perform a competitor analysis for cancer research uk trading limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in E20 area or any other competitors across 12 key performance metrics.
cancer research uk trading limited Ownership
CANCER RESEARCH UK TRADING LIMITED group structure
Cancer Research Uk Trading Limited has no subsidiary companies.
Ultimate parent company
1 parent
CANCER RESEARCH UK TRADING LIMITED
04355631
cancer research uk trading limited directors
Cancer Research Uk Trading Limited currently has 5 directors. The longest serving directors include Mr Simon Ledsham (Feb 2005) and Ms Julie Byard (Oct 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Simon Ledsham | 56 years | Feb 2005 | - | Director | |
| Ms Julie Byard | 57 years | Oct 2018 | - | Director | |
| Mr Philip Almond | 63 years | Jun 2020 | - | Director | |
| Mrs Joanne Shaw | United Kingdom | 61 years | Jan 2022 | - | Director |
| Mr Adrian Walsh | 57 years | Mar 2024 | - | Director |
P&L
March 2024turnover
30.7m
+7%
operating profit
430.8k
0%
gross margin
7.9%
-65.15%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
336k
0%
total assets
10.2m
0%
cash
87k
-0.85%
net assets
Total assets minus all liabilities
Similar Companies
cancer research uk trading limited company details
company number
04355631
Type
Private limited with Share Capital
industry
47910 - Retail sale via mail order houses or via Internet
47190 - Other retail sale in non-specialised stores
96090 - Other personal service activities n.e.c.
incorporation date
January 2002
age
23
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
2 redman place, london, E20 1JQ
Bank
ROYAL BANK OF SCOTLAND(IOM)LTD, ROYAL BANK OF SCOTLAND(IOM)LTD
Legal Advisor
WITHERS LLP
cancer research uk trading limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to cancer research uk trading limited.
cancer research uk trading limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for CANCER RESEARCH UK TRADING LIMITED. This can take several minutes, an email will notify you when this has completed.
cancer research uk trading limited Companies House Filings - See Documents
| date | description | view/download |
|---|
